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Protocol
AbstrACt
Introduction Type 2 diabetes (T2D) is a leading health 
priority worldwide. Multimorbidity (MM) is a term 
describing the co-occurrence of two or more chronic 
diseases or conditions. The majority of people living with 
T2D have MM. The relationship between MM and mortality 
and glycaemia in people with T2D is not clear.
Methods and analysis Medline, Embase, Cumulative Index 
of Nursing and Allied Health Complete, The Cochrane Library, 
and SCOPUS will be searched with a prespecified search 
strategy. The searches will be limited to quantitative empirical 
studies in English with no restriction on publication date. 
One reviewer will perform title screening and two review 
authors will independently screen the abstract and full texts 
using Covidence software, with disagreements adjudicated 
by a third reviewer. Data will be extracted using a using a 
Population, Exposure, Comparator and Outcomes framework. 
Two reviewers will independently extract data and undertake 
the risk of bias (quality) assessment. Disagreements will 
be resolved by consensus. A narrative synthesis of the 
results will be conducted and meta-analysis considered 
if appropriate. Quality appraisal will be undertaken using 
the Newcastle-Ottawa quality assessment scale and the 
quality of the cumulative evidence of the included studies 
will be assessed using the Grading of Recommendations, 
Assessment, Development and Evaluation approach. 
This protocol was prepared in adherence to the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses 
Protocols guidelines to ensure the quality of our review.
Ethics and dissemination This review will synthesise 
the existing evidence about the impact of MM on mortality 
and glycaemic outcomes in people living with T2D and 
increase our understanding of this subject and will inform 
future practice and policy. Findings will be disseminated 
via conference presentations, social media and peer-
reviewed publication.
PrOsPErO registration number CRD42017079500.
IntrOduCtIOn
rationale
Type 2 diabetes (T2D) is a major health 
priority of the 21st century. Worldwide, it 
is estimated that more than 424 million 
people live with diabetes, resulting in 
US$727 billion in healthcare expenditures.1 
Approximately 4 million people die from 
diabetes-related causes each year, equiva-
lent to 1 death every 8 s, with nearly half of 
these deaths in people under the age of 60.1 
There is no doubt that T2D imposes a heavy 
burden on communities.
The management of T2D is complex, 
requiring continuous efforts to implement 
recommendations for self-management 
and pharmacotherapy in a stepwise manner 
to achieve evidence-based targets. This 
complexity is increased when the patient 
has other chronic conditions in addition to 
T2D because T2D rarely occurs on its own. 
Data suggest that as many as 85% of those 
with T2D have at least one other chronic 
condition,2 which is higher than the 52% in 
the general population that is multimorbid.3
For many years, the terms comorbidity 
and multimorbidity (MM) were used inter-
changeably.4 It has only been more recently 
that there has been a clearer distinction 
and understanding between the two terms. 
strengths and limitations of this study
 ► This will be the first systematic review to explore the 
impact of multimorbidity (MM) on all-cause mortality 
and glycaemia in people with type 2 diabetes (T2D) 
and has the potential to make a valuable contribu-
tion to the literature in this area.
 ► Our review benefits from a comprehensive search 
strategy including key terms, synonyms and med-
ical subject headings that describe the research 
questions with a deliberate inclusion of the ‘comor-
bidity’ term to address the identified issue of the 
terms ‘comorbidity’ and ‘multimorbidity’ being used 
interchangeably.
 ► We expect the literature to be quite heterogeneous 
in terms of how MM is defined and the way out-
comes are reported so that a narrative synthesis 
may be likely.
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Comorbidity is defined as the existence or occurrence 
of any additional condition(s) that co-occurs with an 
index disease.5 MM however refers to the presence of 
two or more chronic conditions in an individual, with 
no reference to an index condition.6 These established 
definitions provide the basis of our systematic review 
which exclusively focuses on MM in T2D.
MM presents multiple challenges. It is associ-
ated with a reduced quality of life, increased costs, a 
reduced ability to make lifestyle changes and may be 
associated with complex therapeutic regimens which 
the patient may be challenged to manage.7 For health 
professionals, MM brings increased workload and the 
clinical challenges of interactions between multiple 
conditions and medications.4 Most condition-specific 
management guidelines do not account for MM and 
prioritise management of one condition at the expense 
of another.7 For people with diabetes, this can lead to 
clinicians focusing on diabetes only without consid-
eration of the patient’s other conditions and patient 
goals. Similarly, a focus on other conditions may lead 
to suboptimal glycaemic management due to a lack of 
focus on diabetes-specific care goals.8 9 This is partic-
ularly problematic because achieving and maintaining 
glycaemic targets early is important in reducing down-
stream complications and all-cause mortality.10
Currently, little is known about the associations 
between MM and T2D. In particular, there is little 
information regarding the relationship of the total 
burden of disease reflected in MM’s multiple dimen-
sions to the association between all-cause mortality 
and glycaemia.
Our systematic review will focus on current knowl-
edge regarding the impact of MM on mortality and 
glycaemia in people with T2D and provide insights 
regarding the implications of MM in the context of this 
chronic disease. It may provide an important founda-
tion of knowledge for improving care for patients with 
T2D and multiple chronic conditions.
Objectives
The primary objective of our systematic review is to 
determine the impact of MM reflected in condition 
count on all-cause mortality and glycaemia in people 
with T2D. We will have two primary outcomes of equal 
interest: (1) all-cause mortality; and (2) glycaemia 
(measured by glycated haemoglobin (HbA1c)).
Secondary outcomes of interest include: (1) hypo-
glycaemia, (2) hyperglycaemia and (3) glycaemic 
variability.
MEthOds And AnAlysIs
The Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses Protocols (PRISMA-P) guidelines has 
been used to prepare this protocol.11
Eligibility criteria
Study characteristics/design
All quantitative empirical studies published in the English 
language will be included. Our target studies will be obser-
vational studies that use either longitudinal cohort (retro-
spective and prospective) or cross-sectional designs. While 
we recognise the limitation of cross-sectional studies in 
terms of assessment of temporality, cross-sectional studies 
provide a snapshot of the association between MM count 
and our glycaemia-related outcomes of interest. We will 
have no restrictions on publication date. The search end 
date will be 28 July 2017.
Randomised controlled trials, non-diabetes drug inter-
vention studies, all qualitative studies, case reports, review 
articles and conference abstracts will be excluded as they 
will not give us information on our primary outcomes 
of interest. Randomised controlled trials and non-dia-
betes drug intervention studies have primary objectives 
of testing particular interventions so the effect of MM will 
not be captured, thus inappropriate for our review which 
is focused on the effects on MM. All non-English studies 
will also be excluded.
Population
Our target study population is adults (18 years of age or 
older) with T2D.
Studies including populations of children and adoles-
cents (under 18 years of age) or people without T2D 
(eg, people with prediabetes, type 1 diabetes/gestational 
diabetes/monogenic diabetes) will be excluded. Animal 
studies will also be excluded.
Exposure
The primary exposure of interest is MM count. We will 
accept any type of MM count, which may include a list 
of chronic conditions from a variety of datasets including 
electronic medical records, administrative and prescrip-
tion datasets. Only studies that assess the relationship 
Table 1 Search terms 
Key terms Multimorbidity Diabetes
Outcomes of 
interest:
mortality
glycaemia
Other 
related 
terms or 
synonyms
multimorbid*
multi morbid*
condition count*
multiple condition*
multiple disease*
multiple disorder*
multicondition*
multidisease*
multidisorder*
multi condition*
multi disease*
multi disorder*
comorbid*
co morbid*
diabet*
diabetes 
adj2
(type 2 or 
type ii)
mortality
death
surviv*
surviv*
analys*
glycaemia*
glycemia*
hypoglycaem*
hypoglycem*
hyperglycaem*
hyperglycem*
glycem* varia*
glycaem* varia*
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between a numerical count of MM and our outcomes of 
interest will be included.
Studies with single nominated specific conditions (ie, 
only one comorbid condition) linked with T2D without 
MM count will be excluded.
Comparators (control)
A comparator/control group is defined by people with 
T2D with no other chronic conditions. Studies that do 
not include such a control group will not be excluded.
Outcome
A study will be included in our review if data is provided 
regarding either all-cause mortality or glycaemic 
outcomes. It is expected that glycaemia will be reported in 
the form of HbA1c, however, we will include any measure 
of glycaemia, for example, hypoglycaemia, hypergly-
caemia or glycaemic variability.
Information sources
We will search five electronic databases including Medline 
(Ovid interface), Embase (Ovid interface), Cumulative 
Index of Nursing and Allied Health Complete (EBSCO 
interface), The Cochrane Library (Ovid interface) and 
SCOPUS with no restrictions on publication date.
We will check the International Prospective Register of 
Systematic Reviews regularly for ongoing and completed 
systematic reviews for MM and T2D.
search strategy
The search strategy will include medical subject head-
ings, terms and synonyms relating to or describing our 
primary objectives. These terms will be combined using 
appropriate Boolean logic operators to create our search 
strategy. The truncation symbol (*) will also be included 
at the end of the stem of a word to retrieve all words that 
start with that stem. Our strategy has been reviewed by a 
librarian from a biomedical library and members of our 
review panel with expertise in MM and T2D. A number 
of test runs will first be conducted with Medline, and any 
necessary adjustments will be made prior to running the 
search. Once the search strategy is finalised, the searches 
will be adapted for each of the five electronic databases 
prior to conducting the searches. The search terms are 
listed in table 1. The full search strategy is available in 
online supplementary file 1.
study records
Data management
Literature search results will be downloaded to EndNote 
(V.7; Clarivate Analytics) and duplicates will be removed. 
The non-duplicate studies will then be uploaded to Covi-
dence,12 a systematic review management software, for 
the selection process.
Selection process
The selection process of the studies for inclusion in our 
review will be conducted in three stages. First, titles of 
the studies identified in the five database searches will 
be screened by the primary researcher (JC) against the 
predefined eligibility criteria outlined above. A delib-
erately inclusive approach will be adopted for this title 
screening stage to reduce the risk of missing potentially 
relevant studies.
Second, all abstracts will be screened by two reviewers 
independently. The primary researcher (JC) will screen 
all abstracts against the predefined eligibility criteria 
outlined above to identify a subset of potentially relevant 
studies. An independent second screening of the abstracts 
will be completed between the following reviewers (JMN, 
JF, BN, BJ, AJ, FM). Any inter-reviewer disagreements will 
be discussed and resolved by a third reviewer (JMN, JF).
Finally, we will obtain full-text articles for all studies 
that appear to meet our eligibility criteria after the title 
and abstract screening stages. Full-text screening will be 
conducted by two reviewers independently. The primary 
researcher (JC) will screen all full texts against our 
predefined eligibility criteria. This will then be repeated 
independently by a second reviewer (JMN, JF, BJ). Online 
supplementary material will be consulted when necessary. 
Again, any inter-reviewer disagreements will be discussed 
and resolved by a third reviewer (JMN, JF). Reasons 
for exclusion at the full-text screening process will be 
recorded.
Data extraction
Data will be extracted in a structured manner from all 
included studies and recorded in a predefined data 
extraction form designed by the primary researcher (JC) 
following a prespecified Population, Exposure, Compar-
ator, Outcomes framework in the data extraction stage. 
This is an adapted framework based on the Cochrane 
PICO statement where ‘I’ for intervention is replaced with 
an ‘E’ for exposure. We will also be including an extra 
‘study characteristics’ parameter to record characteris-
tics of the study including study design, setting, period of 
study and aims and objectives (see online supplementary 
file 2). The form will be reviewed, refined and adjusted 
where necessary by the review team. Again, online supple-
mentary material will be consulted when necessary for 
data extraction.
data items
We will be extracting relevant data in each of the following 
five parameters:
Populations
We will extract data on characteristics of study popula-
tions (sample size, sex, age, ethnicity, socioeconomic 
status, occupation, education, diabetes duration, HbA1c, 
insulin treatment and oral antidiabetes drugs), as well as 
definition/measure of T2D, method of recruitment and 
sampling and inclusion and exclusion criteria.
Exposure
We will describe the definition/measure of MM count 
and number of subjects reported.
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Comparator
We will provide details provided in the publication of any 
comparator groups including the definition/measure of 
people with T2D with no other chronic/long-term condi-
tions and numbers in group.
Outcomes
We will provide details as to how all-cause mortality and/
or glycaemia is defined/measured, as well as length of 
follow-up, number of subjects and the statistical analyses 
employed by the authors to evaluate the relationship 
between MM count and the measured outcomes.
Study characteristics
We will extract details of study design, setting, period of 
study and aims and objectives.
Outcomes and prioritisation
One of the primary clinical outcomes of interest is 
all-cause mortality. We expect that studies will calculate 
the effect estimate as either HRs, ORs, incidence rates or 
survival percentages.
For our other primary outcome, glycaemia, we will 
prioritise those studies that measure glycaemia in terms 
of HbA1c. We will further divide studies into one of 
two groups: those that measure HbA1c as a continuous 
variable and those that measure HbA1c as a categorical 
variable.
We will accept all other measures of glycaemia as 
secondary outcomes.
risk of bias assessment (quality assessment in individual 
studies)
Two reviewers will independently assess the risk of bias 
(quality) in each of the included studies.
All studies will be assessed using the Newcastle-Ot-
tawa quality assessment scale.13 The choice of this tool 
was informed by recommendations from the Cochrane 
Handbook on assessing the quality of non-randomised 
studies.14 Any inter-reviewer disagreements will be 
discussed and resolved by a third reviewer.
The Newcastle-Ottawa quality assessment scale has 
a star system to judge three broad perspectives of the 
included studies: the selection of the study groups; the 
comparability of the groups and the ascertainment of the 
outcome of interest.
data synthesis
For data synthesis, we will group the included studies 
according to the two outcomes of all-cause mortality 
and glycaemia. Within the glycaemia outcome group, 
we will further subgroup the studies into the different 
measures of glycaemia. For our primary analysis, we will 
consider either all-cause mortality or glycaemia each as a 
composite outcome. However, dependent on the number 
of studies retrieved, an analysis of glycaemia subtype will 
be conducted. Furthermore, dependent on the character-
istics of the study populations, we will consider stratifying 
our results according to either exposure ascertainment 
(MM count) or population characteristics (ie, age group, 
gender and socioeconomic status).
A narrative synthesis of findings will be conducted 
which will describe the findings from each of the included 
studies. For each study we will present details relating to 
the following:
 ► The number and characteristics of participants in the 
study.
 ► Setting.
 ► Study design.
 ► The outcome-level risk of bias of the study.
 ► Findings for quantitative outcomes.
 ► Inconsistent findings within individual studies will be 
indicated.
If further information relevant to our review is required, 
we will attempt to contact the authors of the included 
studies.
A meta-analysis will be conducted if appropriate. Tests 
for publication bias and heterogeneity will be conducted. 
If the included studies are sufficiently homogenous in 
terms of study design, study population, outcomes and 
data analysis, a meta-analysis will be considered. I2 statistic 
will be used to assess statistical heterogeneity and to guide 
the choice of either fixed or random effects model. Given 
sufficient numbers of included studies, a funnel plot will 
be used to assess publication bias and other reporting 
bias, and a Begg’s test will be used to test for asymmetry. 
A sensitivity analysis will also be used to determine the 
consistency of the results. However, if a meta-analysis and 
the above tests are not possible, possible sources of bias 
across studies will be discussed in the narrative synthesis, 
and this limitation will be considered when drawing 
conclusions.
Confidence in cumulative evidence
Grading of Recommendations, Assessment, Development 
and Evaluation (GRADE) guideline is recommended by 
the Cochrane Handbook for grading the quality and 
strength of evidence.15 We will use the GRADE guide-
lines to assess the quality of evidence for our research 
questions.
Patient and public involvement
Patients were not involved in the development of this 
protocol.
EthICs And dIssEMInAtIOn
Ethics
Ethics was not required for this study as this is a systematic 
review and it does not contain individual patient data. We 
will disseminate the results of our review via conference 
presentations, social media and peer-reviewed publica-
tion. This review also forms part of the lead investigator’s 
(JC) PhD.
dIsCussIOn
This systematic review will aim to synthesise the existing 
evidence on the effects of MM in T2D on mortality and 
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glycaemic control and will be the first on this subject. 
Clinical management in patients with T2D and MM is 
a growing international healthcare challenge, and our 
review will make important contributions to under-
standing of the impact of MM, if any, in the context of 
T2D on key clinical outcomes which should enhance the 
understanding in this field. We hypothesise that increasing 
MM will be associated with increased all-cause mortality; 
however, the effects on glycaemic outcomes may vary. Our 
review will be the first to bring together existing literature 
exploring associations between MM and T2D, and there-
fore clarifying the effects of increasing MM on mortality 
and glycaemia in people with T2D.
Key strengths of our review will be our adherence to the 
PRISMA-P guidelines, our comprehensive search strategy 
and the fact that all screening and data extraction will 
be performed by two reviewers independently. We expect 
the literature to be quite heterogeneous in terms of how 
MM is defined and the way outcomes are reported so a 
narrative synthesis may be likely which may be a limita-
tion. In addition, we have restricted our review to English 
language publications which is a potential limitation.
As the first review on this subject, it will help identify 
what is known on this subject and whether any gaps in 
knowledge exist. It will therefore help highlight whether 
there are areas requiring further investigation as well 
as clarify the key messages from the evidence, to date, 
including implications for future guidelines for those 
with T2D.
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